
Evolance Wellness Inc. Applauds FDA Acknowledgement of NMN's History as a Dietary Supplement



Miami, Florida Oct 16, 2025 (<u>Issuewire.com</u>**)** - In a significant development for the wellness industry, the U.S. Food and Drug Administration (FDA) has reversed its prior position, effectively allowing β-Nicotinamide Mononucleotide (NMN) to be lawfully marketed as a dietary supplement. Evolance Wellness Inc. (<u>Evolance</u>), a performance-wellness company, welcomes the decision as a landmark moment for science, consumer access, and innovation in cellular health.

This regulatory clarification follows extensive efforts by industry advocates, including the Natural Products Association (NPA), which challenged the FDA's previous stance. (Natural Products Association (NPA)) The NPA successfully demonstrated that NMN was marketed as a dietary supplement in the U.S. prior to its investigation as a new drug. This fact, combined with NMN's role as a naturally occurring molecule essential to the body's NAD+ biosynthesis pathway, supports its classification as a dietary supplement under the *Dietary Supplement Health and Education Act* (DSHEA) (1994).

For Evolance, this regulatory clarity is a landmark moment. The decision sets a vital precedent, ensuring that naturally occurring molecules essential to human health can remain accessible as dietary supplements. This protects the pathway for future innovation and supports the principle of consumer choice, allowing individuals to proactively support their cellular health.†

"This is a positive development for consumers and the scientific community," said Andrei G., Head of Product Development at Evolance. "It ensures that innovation can continue and allows individuals to access supplements that support their cellular health and energy metabolism."†

About Evolance Wellness Inc.

Evolance Wellness Inc. is a performance-wellness company producing clean-label, daily supplements designed to support energy, clarity, and recovery.† Guided by its **Dynamic Equilibrium**TM philosophy and **Trust Stack**TM transparency initiative, Evolance develops products built on clinically studied ingredients and third-party testing.

† These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Source: Evolance Wellness Inc.

Media Contact

Evolance Wellness Inc

*******@evolance.com

Source: Evolance Wellness Inc

See on IssueWire